EUVIMEDEUVIMED entdecken
Crossref

Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years

Jeremy Samuel Faust iD, Ashish Kumar, Jui Shah, Sumanth Khadke, Sourbha S Dani, Sarju Ganatra iD, Paul E Sax

Clinical Infectious Diseases · 11.11.2023 · 77 (9) · 1257-1264

DOI: 10.1093/cid/ciad400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 30.06.2023. Verfasst von Jeremy Samuel Faust und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Health Policy and Public Health, Department of Emergency Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massa…. Hauptthemen laut MEDLINE: COVID-19, Asthma, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effects of nirmatrelvir/ritonavir (NMV/r [Paxlovid]) on coronavirus disease 2019 (COVID-19) outcomes in younger vaccinated adults are unclear. The objective of this study was to assess if NMV/r use in vaccinated adults aged ≤50 years is associated with improved outcomes and to identify beneficial and nonbeneficial subgroups.

Methods

In this cohort study, we generated 2 propensity-matched cohorts of 2547 patients from an 86 119-person cohort assembled from the TriNetX database. Patients in 1 cohort received NMV/r, and patients in the matched control cohort did not. The main outcome was composite of all-cause emergency department visits, hospitalization, and mortality.

Results

The composite outcome was detected in 4.9% of the NMV/r cohort and 7.0% of the non-NMV/r cohort (odds ratio, 0.683 [95% confidence interval, .540–.864]; P = .001), indicating a 30% relative risk reduction. The number needed to treat (NNT) for the primary outcome was 47. Subgroup analyses found significant associations for patients with cancer (NNT = 45), cardiovascular disease (NNT = 30), and both conditions (NNT = 16). No benefit was found for patients with only chronic lower respiratory disorders (asthma/chronic obstructive pulmonary disease [COPD]) or without serious comorbidities. Thirty-two percent of NMV/r prescriptions in the overall database were for 18- to 50-year-olds.

Conclusions

NMV/r use in vaccinated adults aged 18–50 years, especially with serious comorbidities, was associated with reduced all-cause hospital visits, hospitalization, and mortality in the first 30 days of COVID-19 illness. However, NMV/r in patients without significant comorbidities or with only asthma/COPD had no association of benefit. Therefore, identifying high-risk patients should be a priority and overprescription should be avoided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AsthmaPulmonary Disease, Chronic ObstructiveHumansAdultRitonavirCOVID-19 Drug TreatmentCohort StudiesAntiviral AgentsDrug CombinationsLactamsLeucineNitrilesProline

Stichwörter der Autor:innen

COVID-19PaxlovidSARS-CoV-2nirmatrelvirvaccinated

Substanzen

RitonavirAntiviral Agentsnirmatrelvir and ritonavir drug combinationDrug CombinationsLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Division of Health Policy and Public Health, Department of Emergency Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Cleveland Clinic Akron General, Akron, Ohio, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Vermont, USA.
  • Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Jeremy Samuel Faust, Sarju Ganatra

Zitieren

APA

Faust, J. S., Kumar, A., Shah, J., Khadke, S., Dani, S. S., Ganatra, S., & Sax, P. E. (2023). Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years. Clinical Infectious Diseases, 77(9), 1257-1264. https://doi.org/10.1093/cid/ciad400

Vancouver

Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, et al. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years. Clinical Infectious Diseases. 2023;77(9):1257-1264. doi:10.1093/cid/ciad400

BibTeX
@article{Faust2023,
  author = {Faust, Jeremy Samuel and Kumar, Ashish and Shah, Jui and Khadke, Sumanth and Dani, Sourbha S and Ganatra, Sarju and Sax, Paul E},
  title = {Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {9},
  pages = {1257--1264},
  doi = {10.1093/cid/ciad400}
}
Kostenlos starten →